Ocugen Doses First Patient in Phase 3 Registrational Trial for OCU410 Modifier Gene Therapy for Geographic Atrophy, Following RMAT Designation

September 6, 2026

GlobeNewswire USA

Overview

Ocugen has initiated patient dosing in its Phase 3 registrational trial for OCU410, a modifier gene therapy targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). OCU410 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA on July 29, 2026, based on promising Phase 2 clinical data demonstrating a favorable safety and efficacy profile. This advancement offers new hope for GA patients with limited treatment options and marks a critical step towards regulatory approval for a potentially transformative gene therapy.

In Depth

Key Findings

Ocugen, Inc. has announced the dosing of the first patient in its Phase 3 registrational trial for OCU410, a groundbreaking modifier gene therapy aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). This significant progression into late-stage clinical development follows the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation granted to OCU410 on July 29, 2026, based on compelling Phase 2 clinical data. The initiation of this Phase 3 trial is a pivotal step towards bringing a novel therapeutic option to patients grappling with a condition for which current treatments are severely limited.

Technical / Clinical Details

OCU410 is an adeno-associated virus (AAV)-based gene therapy designed to deliver multiple complementary pathway genes into retinal cells within the eye. This multi-pronged approach aims to address the complex pathophysiology of GA by modulating various factors involved in the complement cascade, a key driver of disease progression. Previous Phase 2 clinical trials demonstrated a favorable safety profile for OCU410, with promising signals of visual acuity stabilization and improvement. The RMAT designation from the FDA signifies that OCU410 is recognized as a regenerative medicine advanced therapy intended to treat a serious or life-threatening disease, and this designation facilitates expedited development and review processes. The ongoing Phase 3 registrational trial will rigorously evaluate the safety and efficacy of OCU410 in a larger patient cohort, providing the essential data for a future Biologics License Application (BLA) submission to the FDA. Current therapeutic interventions for GA are limited to slowing disease progression, making OCU410’s potential for sustained, single-dose effects a highly anticipated development for enhancing patients’ quality of life.

Background & Context

Dry AMD is a leading cause of adult blindness in developed countries, and GA, its advanced form, results in severe central vision loss, profoundly impacting daily activities like reading and facial recognition. The substantial unmet medical need for effective GA treatments has spurred intense research and development in the ophthalmic space. The dysregulation of the complement system is widely accepted as a primary pathogenic mechanism in GA, and OCU410’s strategy of targeting multiple complement pathway components holds promise for a broader therapeutic impact compared to approaches that address single factors. The RMAT designation is a critical regulatory pathway established by the FDA to accelerate the development and approval of regenerative medicine products, ensuring that promising therapies reach patients more quickly. Beyond gene therapy, the field of ophthalmic regenerative medicine is actively exploring stem cell therapies and other innovative approaches to restore and preserve vision.

Strategic Significance & Outlook

The progression of Ocugen’s OCU410 into Phase 3, coupled with its RMAT designation, positions it as a frontrunner in transforming GA treatment. Successful completion of this trial could lead to OCU410 becoming the first approved gene therapy for GA, offering a potentially curative or significantly disease-modifying option that overcomes the limitations of existing therapies. The comprehensive data gathered during this large-scale Phase 3 study will be crucial for securing regulatory approval and subsequently introducing OCU410 to the market. If the therapy demonstrates durable visual benefits with a single administration, it could not only significantly improve patient outcomes but also reduce the long-term burden on healthcare systems. The forthcoming clinical results and subsequent regulatory decisions will be pivotal in determining the commercial viability and future trajectory of OCU410 and, by extension, the landscape of GA management.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE74WeIo8Vbnk_LcYV75gfSq014Y1YMkU9iRystQgAXuWSTDpnvmOD969MN0wSLyf9SwMpoHRAFOIi54pUfecWw7GGxbr4WblBaSr6K05i_X9v5vIEVrNTYjZ4W9HW6UdDV_zBCrb27HWJZV2Cv-oQgzB-LEf-RCGOezd6XMGamk75BDbgmnoaU1f2NPbE25PglgpGiW7phqdNdgxqvRN88mA_OCr0v4G1hLZRy7o2UBJuv1o6-HAApTp1RD2RVZGB4W1Gv9G8R5EZ-o2pzrS2Zzrr_jn9mmQMjBPMPHLY5uR-PbCzBWhqbhSA80HErj0qj1Tz65po8beWTWDNsu-6iDjKTHXBEUU8JxWUem5mLtPtbvgEAjwUc5qwWOEoQPWDtV7nySGwebw-DzKKBYdNI

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.